New hope for pancreatic cancer? immunotherapy cocktails tested in major trial

NCT ID NCT03193190

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested several immunotherapy-based drug combinations in 341 people with metastatic pancreatic cancer. Participants were split into two groups: those who had not yet received treatment and those who had already tried one type of chemotherapy. The goal was to see if these combinations were safe and could shrink tumors. The trial is now complete, and results will help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (an immunotherapy drug) combined with standard chemotherapy drugs (nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, fluorouracil)
What this could lead to: If successful, this could point toward better treatment options for people with metastatic pancreatic cancer, potentially improving survival and quality of life.
What could go wrong: This is an early-phase study (Phase 1/2) with a small number of participants, so results may not apply to everyone. Immunotherapy combinations can cause serious side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Clínica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Columbia University

New York, New York, 10032, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Helen Diller Fam Comp Can Ctr

San Francisco, California, 94158, United States
Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
Hosp. G. U Gregorio Marañón

Madrid, 28007, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28037, Spain
Hospital Universitario Vall d Hebron

Barcelona, 08035, Spain
Kanagawa Cancer Center

Kanagawa, 241-8515, Japan
Lombardi Cancer Center, Georgetown University

Washington D.C., District of Columbia, 20007, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
MorristownMedicalCenter

Morristown, New Jersey, 07962, United States
National Cancer Center Hospital

Tokyo, 104-0045, Japan
National Cancer Center Hospital East

Chiba, 277-8577, Japan
Oregon Health and Science University

Portland, Oregon, 97239, United States
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Smilow Cancer Hospital at Yale New Haven

New Haven, Connecticut, 06510, United States
Uni of Chicago Medical Center

Chicago, Illinois, 60637, United States
Universitätsklinikum Essen

Essen, 45122, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.